<DOC>
	<DOCNO>NCT00201916</DOCNO>
	<brief_summary>To improve management patient early stage prostate cancer .</brief_summary>
	<brief_title>Shorter Radiation Schedule Treatment Prostate Cancer</brief_title>
	<detailed_description>To compare efficacy short radiation fractionation schedule prostate ( 5250 cGy/20 fraction 28 day ) conventional schedule ( 6600 cGy/33 fraction 45 day ) men receive radiotherapy Stage T1a moderately poorly differentiate , T1b , T1c , T2 prostate cancer . The primary outcome local control prostate secondary outcome include toxicity , disease free survival , survival , quality life economics .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>histologic diagnosis adenocarcinoma prostate evidence metastatic disease node , bone lung stage T1a moderately poorly differentiate , T1b , T1c T2 current UICCTNM classification PSA &gt; 40 mcg/L previous therapy carcinoma prostate biopsy TURP , include patient previously hormone therapy treatment prostate cancer prior active malignancy nonmelanoma skin cancer ; colon thyroid cancer treat minimum five year prior study entry presume cured simulated volume exceeds 1000 cm3 previous pelvic radiotherapy inflammatory bowel disease serious nonmalignant disease would preclude radiotherapy surgical biopsy geographic inaccessibility followup psychiatric addictive disorder would preclude obtain informed consent adherence protocol unable commence radiation therapy within 26 week date last prostatic biopsy failure give inform consent participate study</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prostate specific antigen</keyword>
	<keyword>PSA</keyword>
	<keyword>radiation fractionation</keyword>
</DOC>